Mr. Cali is a Managing Partner at Noble Capital Markets, Inc. Nathan Cali has more than 18 years of Capital Markets experience. He has been a lead Managing Director/Head of the Healthcare and Life Sciences Investment Banking and Advisory franchise at Noble since 2017 and, was previously a sell-side equity analyst for 9 years. Mr. Cali is a Board Member of Precise Bio, a tissue engineering, biomaterials, cell technologies, including, cardiology, orthopedics, and dermatology. He was previously a Board observer of Eledon Pharmaceuticals (ELDN:NASDAQ, f.k.n.a. Anelixis Therapeutics, Inc.), a phase II biotechnology company. Mr. Cali has been quoted in most business journals including Reuters and the Washington Business Journal for his work as a sells-side analyst. Mr. Cali started his corporate career at Andrx Corporation, a public pharmaceuticals company. Mr. Cali was a corporate manager dealing in finance, state taxation, corporate governance, patents, distribution, and business development for the firm. Andrx was purchased by Watson Pharmaceuticals in 2006 for $2.0 billion in cash. Prior to joining NOBLE, Mr. Cali gained investment experience as a portfolio account analyst/manager at Franklin Templeton Investments. Mr. Cali holds a B.S. in Finance from The Florida State University and an M.B.A. in Finance and an MBA in Real Estate Development from Nova Southeastern University. Nathan also currently holds series 7, 79, 86, and 87 FINRA designations.